HIRONC

Hironic Inc. (CEO Jinwoo Lee), a leading aesthetic medical device company, announced on the 24th that it has signed new export contracts with distributors in Singapore and Malaysia. This comes just two weeks after securing a major KRW 48.4 billion (approx. USD 35.5 million) supply agreement for its SYNERJET device in the North American market.

According to a company official, “We recently signed agreements with key Asian distributors to export our flagship devices, including NEW DOUBLO 2.0 and SYNERJET. We aim to diversify our sales channels throughout Asia and increase our export ratio.”

Hironic is actively expanding its supply chain to accelerate sales recovery in Asia. The company has completed construction of its second and third manufacturing plants in Osong, Chungbuk Province, enhancing its production infrastructure. This expansion is expected to improve manufacturing efficiency and ensure a stable global supply to meet rising overseas demand. The company also aims to facilitate the resumption of stock trading by demonstrating robust operational capabilities.

SYNERJET, Hironic’s core product, utilizes a combination of Microjetting, Plasma, and Electroporation technologies to deliver skin booster ingredients without the use of needles. It offers the advantage of reduced pain and minimal downtime, making it highly attractive in both Asian and Western aesthetic markets.

Previously, on November 10, Hironic signed a conditional supply agreement with a North American medical device distributor worth KRW 48.4 billion, approximately 1.5 times the company’s 2024 annual revenue of KRW 31.6 billion. The contract runs through October 2030 and is contingent upon obtaining U.S. FDA and Canada MDEL approvals. The company anticipates FDA clearance in the first half of next year. Under the agreement, 50% of the payment is made at the time of order, with the remaining 50% prior to shipment.

Hironic is now at a pivotal point in its global expansion, driven by strategic partnerships across Asia and North America. Key challenges ahead include timely regulatory approvals, activation of local sales networks, and brand-building efforts in new international markets.​